DM4-SPDB-acid serves as a drug-linker conjugate comprised of the maytansine-derived payload DM4, known for its tubulin-inhibiting properties, linked via an SPDB linker, resulting in a highly effective treatment with strong anti-tumor capabilities. It is suitable to be conjugated into antibody-drug conjugates (ADCs). The terminal carboxylic acid can react with primary amine groups in the presence of activators such as HATU. Reagent grade, for research purpose. Please contact us for GMP-grade inquiries.
Usually ships within 24 hours.